Prediction of long-term outcome by percent improvement after the first day of thrombolytic treatment in stroke patients

J Neurol Sci. 2009 Jun 15;281(1-2):69-73. doi: 10.1016/j.jns.2009.02.365. Epub 2009 Mar 21.

Abstract

Background: We investigated a method for assessing early improvement and predictive factors of early and late outcomes in patients receiving thrombolytic therapy.

Methods: A total of 160 consecutive patients who received thrombolytic therapy were included in the study. Using National Institutes of Health Stroke Scale (NIHSS) scores, percent improvement [(baseline NIHSS score-24-hour NIHSS score)/baseline NIHSS score x 100] was calculated and compared with delta (baseline NIHSS score-24-hour NIHSS score) and with major neurological improvement (MNI, NIHSS score of 0-1 or >or=8 point improvement at 24 h) by receiver operating characteristic (ROC) curve analysis. Finally, we investigated the independent predictors of improvement at 24 h after the thrombolytic therapy and of favorable 3-month outcome (modified Rankin scale score 0-2).

Results: By pairwise comparison of ROC curves, percent improvement was stronger than delta (p=0.004) and MNI (p<0.001) in predicting long-term outcome. First day improvement (FDI), defined as greater than 20% improvement, was a strong predictor of favorable 3-month outcome (OR 12.55, 95% CI 5.41-29.10). Recanalization (OR 3.30, 95% CI 1.28-8.45), absence of carotid T occlusion (OR 0.09, 95% CI 0.02-0.42) and hemorrhagic transformation (OR 0.25, 95% CI 0.09-0.73) were independent predictors of FDI. Independent predictors of favorable 3-month outcome were FDI, current smoking, absence of carotid T occlusion and hemorrhagic transformation.

Conclusions: Percent improvement at 24 h after thrombolytic therapy is a useful surrogate marker for predicting the long-term outcome. Our findings highlight the importance of early stroke management.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged
  • Atrial Fibrillation / complications
  • Carotid Artery Diseases / complications
  • Female
  • Fibrinolytic Agents / therapeutic use*
  • Humans
  • Injections, Intra-Arterial
  • Injections, Intravenous
  • Male
  • Middle Aged
  • ROC Curve
  • Severity of Illness Index
  • Smoking
  • Stroke / complications
  • Stroke / drug therapy*
  • Stroke / physiopathology
  • Thrombolytic Therapy*
  • Tissue Plasminogen Activator / therapeutic use*
  • Treatment Outcome
  • Urokinase-Type Plasminogen Activator / therapeutic use*

Substances

  • Fibrinolytic Agents
  • Tissue Plasminogen Activator
  • Urokinase-Type Plasminogen Activator